US 12,251,376 B2
Combinations with thiazolidinediones for use in the prevention or treatment of abnormal bone growth
Rodolfo Gómez Bahamonde, Santiago de Compostela (ES); Eloi Franco Trepat, Santiago de Compostela (ES); Ana Alonso Pérez, Santiago de Compostela (ES); María Guillán Fresco, Santiago de Compostela (ES); and Alberto Jorge Mora, Santiago de Compostela (ES)
Assigned to SERVIZO GALEGO DE SAÚDE (SERGAS), Santiago de Compostela (ES); and FUNDACIÓN PÚBLICA GALEGA INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA, Santiago de Compostela (ES)
Appl. No. 17/429,902
Filed by SERVIZO GALEGO DE SAÚDE (SERGAS), Santiago de Compostela, A Coruña (ES); and FUNDACIÓN PÚBLICA GALEGA INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA, Santiago de Compostela (ES)
PCT Filed Feb. 10, 2020, PCT No. PCT/EP2020/053344
§ 371(c)(1), (2) Date Aug. 10, 2021,
PCT Pub. No. WO2020/165101, PCT Pub. Date Aug. 20, 2020.
Claims priority of application No. 19382094 (EP), filed on Feb. 11, 2019.
Prior Publication US 2022/0288044 A1, Sep. 15, 2022
Int. Cl. A61K 31/405 (2006.01); A61K 31/4439 (2006.01); A61K 31/573 (2006.01); A61P 19/08 (2006.01)
CPC A61K 31/4439 (2013.01) [A61K 31/405 (2013.01); A61K 31/573 (2013.01); A61P 19/08 (2018.01)] 10 Claims
 
1. A method for preventing or treating abnormal bone growth in a subject, the method comprising administering to the subject a therapeutically effective amount of a combination drug product comprising:
a thiazolidinedione selected from the group consisting of rosiglitazone, pioglitazone, or a combination thereof;
a corticoid comprising dexamethasone; and
an anti-inflammatory drug comprising indomethacin.